Agyany Pharma

Company Overview

Snapshot

Founded in April 2026, Agyany Pharma is led by Co-Founder and Chief Medical Officer Prof. Dr. Ari Zimran. The company operates with 1–10 employees and is currently in the Pre-Funding stage, focusing on advancing its lead program for Parkinson's disease through clinical development.

Business overview

Agyany Pharma is a clinical-stage biopharmaceutical company specializing in the development of disease-modifying treatments for Parkinson's disease and related neurodegenerative disorders. The company's core product strategy involves repurposing Ambroxol to target the underlying molecular mechanisms of GBA1-associated Parkinson's disease, moving beyond symptomatic treatment. Operating within the Health Tech & Life Sciences sector, specifically Pharma & Medical Biotechnology and Drugs Discovery & Development, Agyany Pharma combines clinical expertise, genetics, and neuroscience to advance novel therapies through clinical development, aiming to improve patient outcomes.

Company Intelligence Q&A

What is Agyany Pharma's primary focus?

Agyany Pharma is focused on developing disease-modifying therapies for Parkinson's disease and related neurodegenerative disorders.

When was Agyany Pharma founded?

Agyany Pharma was founded in April 2026.

Who is a key founder of Agyany Pharma?

Prof. Dr. Ari Zimran is a Co-Founder and Chief Medical Officer at Agyany Pharma.

What is the current product stage of Agyany Pharma's therapies?

Agyany Pharma's therapies are currently in the Clinical Trial product stage, focusing on advancing its lead program for Parkinson's disease through clinical development.

Which sector does Agyany Pharma operate in?

Agyany Pharma operates in the Health Tech & Life Sciences sector, specifically within Pharma & Medical Biotechnology and Drugs Discovery & Development.